Mario Presti

Herlev, 2730, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Corrigendum to "Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma" [Eur J Cancer 234 (2026) 116200].

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 21, 2026

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2026

Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform.

Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform.

Journal: Cells

Published: November 13, 2025

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 23, 2025

Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types: A Reconstructed Individual Patient Data Analysis.

Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types: A Reconstructed Individual Patient Data Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: July 08, 2025

Acquired resistance to immunotherapy in solid tumors.

Acquired resistance to immunotherapy in solid tumors.

Journal: Trends in molecular medicine

Published: November 28, 2024

Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.

Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 21, 2022

Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.

Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.

Journal: Cancer immunology research

Published: April 22, 2022

Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.

Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions.

Journal: Expert opinion on biological therapy

Published: April 13, 2022

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.

Journal: Frontiers in immunology

Published: May 05, 2021

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma.

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma.

Journal: Cancers

Published: October 07, 2020

The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro.

The effects of targeted immune-regulatory strategies on tumor-specific T-cell responses in vitro.

Journal: Cancer immunology, immunotherapy : CII

Published: July 18, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026